Risk of severe COVID in solid organ transplant recipient.
Journal
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
ISSN: 1988-9518
Titre abrégé: Rev Esp Quimioter
Pays: Spain
ID NLM: 9108821
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
ppublish
Résumé
Despite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SOT contribute to more risk of severe infection. Immunosuppression also blunts the intensity of humoral and cellular responses after vaccination, even when several booster doses have been administered. Still, vaccination is the best strategy to prevent a fatal outcome in case of SARS-CoV-2 infection, with a particular reduction in mortality. SOT recipients should be considered a high-risk population that need yearly SARS-CoV-2 vaccination.
Identifiants
pubmed: 37997864
doi: 10.37201/req/s01.04.2023
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-17Informations de copyright
©The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).